Wihuri Research Institute, Helsinki, Finland.
Translational Cancer Medicine Program, Faculty of Medicine.
Blood. 2020 Oct 15;136(16):1871-1883. doi: 10.1182/blood.2020005699.
Hematopoietic stem cells (HSCs) reside in the bone marrow (BM) stem cell niche, which provides a vital source of HSC regulatory signals. Radiation and chemotherapy disrupt the HSC niche, including its sinusoidal vessels and perivascular cells, contributing to delayed hematopoietic recovery. Thus, identification of factors that can protect the HSC niche during an injury could offer a significant therapeutic opportunity to improve hematopoietic regeneration. In this study, we identified a critical function for vascular endothelial growth factor-C (VEGF-C), that of maintaining the integrity of the BM perivascular niche and improving BM niche recovery after irradiation-induced injury. Both global and conditional deletion of Vegfc in endothelial or leptin receptor-positive (LepR+) cells led to a disruption of the BM perivascular niche. Furthermore, deletion of Vegfc from the microenvironment delayed hematopoietic recovery after transplantation by decreasing endothelial proliferation and LepR+ cell regeneration. Exogenous administration of VEGF-C via an adenoassociated viral vector improved hematopoietic recovery after irradiation by accelerating endothelial and LepR+ cell regeneration and by increasing the expression of hematopoietic regenerative factors. Our results suggest that preservation of the integrity of the perivascular niche via VEGF-C signaling could be exploited therapeutically to enhance hematopoietic regeneration.
造血干细胞 (HSCs) 存在于骨髓 (BM) 干细胞龛位中,该龛位为 HSC 调节信号提供了重要的来源。辐射和化疗会破坏 HSC 龛位,包括其窦状血管和血管周细胞,导致造血恢复延迟。因此,鉴定在损伤期间能够保护 HSC 龛位的因子,可能为改善造血再生提供重要的治疗机会。在这项研究中,我们确定了血管内皮生长因子-C (VEGF-C) 的一个关键功能,即维持 BM 血管周龛位的完整性,并改善辐射诱导损伤后的 BM 龛位恢复。内皮细胞或瘦素受体阳性 (LepR+) 细胞中 Vegfc 的全局和条件缺失都会导致 BM 血管周龛位的破坏。此外,微环境中 Vegfc 的缺失通过减少内皮细胞增殖和 LepR+细胞再生,延迟了移植后的造血恢复。通过腺相关病毒载体进行外源性 VEGF-C 给药可通过加速内皮细胞和 LepR+细胞的再生,并增加造血再生因子的表达,改善辐射后的造血恢复。我们的研究结果表明,通过 VEGF-C 信号维持血管周龛位的完整性可能会被开发为一种治疗方法,以增强造血再生。